These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 26638593

  • 21. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
    Harders SW, Madsen HH, Hjorthaug K, Arveschoug AK, Rasmussen TR, Meldgaard P, Hoejbjerg JA, Pilegaard HK, Hager H, Rehling M, Rasmussen F.
    Cancer Imaging; 2014 Jun 03; 14(1):23. PubMed ID: 25608616
    [Abstract] [Full Text] [Related]

  • 22. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A, Boada M, Cabañas M, Sanchez M, Arguis P, Lomeña F, Ramirez J, Molins L.
    Eur J Cardiothorac Surg; 2012 Jul 03; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [Abstract] [Full Text] [Related]

  • 23. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
    Kremer R, Peysakhovich Y, Dan LF, Guralnik L, Kagna O, Nir RR, Bar-Shalom R.
    Ann Nucl Med; 2016 Feb 03; 30(2):114-21. PubMed ID: 26613715
    [Abstract] [Full Text] [Related]

  • 24. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, Chung MP, Lee KS, Shim YM, Han J, Um SW.
    Respirology; 2010 Nov 03; 15(8):1179-84. PubMed ID: 20573058
    [Abstract] [Full Text] [Related]

  • 25. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M, Erelel M, Ece T, Mudun A.
    Clin Nucl Med; 2007 Aug 03; 32(8):607-12. PubMed ID: 17667432
    [Abstract] [Full Text] [Related]

  • 26. Is there any improvement in clinical staging with 18F-FDG PET/CT compared to surgical staging in cases of lung cancer?
    Gedik GK, Yilmaz F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Aug 03; 38(6):348-354. PubMed ID: 31378538
    [Abstract] [Full Text] [Related]

  • 27. Contrast enhanced CT versus integrated PET-CT in pre-operative nodal staging of non-small cell lung cancer.
    Ceylan N, Doğan S, Kocaçelebi K, Savaş R, Çakan A, Çağrici U.
    Diagn Interv Radiol; 2012 Aug 03; 18(5):435-40. PubMed ID: 22374706
    [Abstract] [Full Text] [Related]

  • 28. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
    Abramyuk A, Appold S, Zöphel K, Hietschold V, Baumann M, Abolmaali N.
    Lung Cancer; 2012 Nov 03; 78(2):148-52. PubMed ID: 22922126
    [Abstract] [Full Text] [Related]

  • 29. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL, Asmuth JC, Alpert NM, Halpern EF, Fischman AJ.
    J Comput Assist Tomogr; 2003 Nov 03; 27(4):479-84. PubMed ID: 12886128
    [Abstract] [Full Text] [Related]

  • 30. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
    Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, Bockisch A, Debatin JF, Freudenberg LS.
    Radiology; 2003 Nov 03; 229(2):526-33. PubMed ID: 14512512
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Utility of FDG PET-CT in CT Stage IA non-small cell lung cancer: The New Zealand Te Whatu Ora Northern region experience.
    Kelly RJ, Anderson GD, Joshi BS, Donald JJ.
    J Med Imaging Radiat Oncol; 2024 Sep 03; 68(6):645-650. PubMed ID: 38941179
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
    Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, Clarke CP, McKay WJ.
    Eur J Cardiothorac Surg; 1999 Sep 03; 16 Suppl 1():S25-30. PubMed ID: 10536941
    [Abstract] [Full Text] [Related]

  • 36. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S.
    Eur J Cardiothorac Surg; 2013 Jul 03; 44(1):83-7. PubMed ID: 23233074
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer.
    Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, Shimizu K, Nakata M.
    Ann Nucl Med; 2013 Jul 03; 27(6):515-22. PubMed ID: 23504519
    [Abstract] [Full Text] [Related]

  • 39. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 40. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF, Liu Y, Zhang JH, Zhou RS, Zhou FH, Yuan MH.
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb 05; 28(2):108-11. PubMed ID: 15854393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.